Recombinant Human RCHY1 293 Cell Lysate

• Cat.No.: RCHY1-2444HCL

Specification

• Description: Antigen standard for ring finger and CHY zinc finger domain containing 1 (RCHY1), transcript variant 1 is a lysate prepared from HEK293T cells transiently transfected with a TrueORF gene-carrying pCMV plasmid and then lysed in RIPA Buffer. Protein concentration was determined using a colorimetric assay. The antigen control carries a C-terminal Myc/DDK tag for detection.
• Source: HEK 293 cells
• Species: Human
• Components: This product includes 3 vials: 1 vial of gene-specific cell lysate, 1 vial of control vector cell lysate, and 1 vial of loading buffer. Each lysate vial contains 0.1 mg lysate in 0.1 ml (1 mg/ml) of RIPA Buffer (50 mM Tris-HCl pH7.5, 250 mM NaCl, 5 mM EDTA, 50 mM NaF, 1% NP40). The loading buffer vial contains 0.5 ml 2X SDS Loading Buffer (125 mM Tris-Cl, pH6.8, 10% glycerol, 4% SDS, 0.002% Bromophenol blue, 5% beta-mercaptoethanol).
• Size: 0.1 mg
• Storage Instruction: Store at -80°C. Minimize freeze-thaw cycles. After addition of 2X SDS Loading Buffer, the lysates can be stored at -20°C. Product is guaranteed 6 months from the date of shipment.
• Applications: ELISA, WB, IP. WB: Mix equal volume of lysates with 2X SDS Loading Buffer. Boil the mixture for 10 min before loading (for membrane protein lysates, incubate the mixture at room temperature for 30 min). Load 5 ug lysate per lane.

Gene Information

• Gene Name: RCHY1 ring finger and CHY zinc finger domain containing 1, E3 ubiquitin protein ligase [ Homo sapiens ]
• Official Symbol: RCHY1
• Synonyms: RCHY1; ring finger and CHY zinc finger domain containing 1, E3 ubiquitin protein ligase; ring finger and CHY zinc finger domain containing 1 , zinc finger protein 363 , ZNF363; RING finger and CHY zinc finger domain-containing protein 1; androgen receptor N terminal interacting protein; ARNIP; CHIMP; DKFZp586C1620; p53 induced protein with a RING H2 domain; PIRH2; PRO1996; RNF199; hPirh2; RING finger protein 199; zinc finger protein 363; p53-induced RING-H2 protein; E3 ubiquitin-protein ligase Pirh2; CH-rich interacting match with PLAG1; p53-induced protein with a RING-H2 domain; androgen-receptor N-terminal-interacting protein; PIRH2E; PIRH2F; ZNF363; hARNIP
• Gene ID: 25898
• mRNA Refseq: NM_001008925
• Protein Refseq: NP_001008925
• MIM: 607680
• UniProt ID: Q96PM5
• Chromosome Location: 4q21.1-q21.3
• Pathway: Adaptive Immune System, organism-specific biosystem; Androgen Receptor Signaling Pathway, organism-specific biosystem; Antigen processing: Ubiquitination and Proteasome degradation, organism-specific biosystem; Class I MHC mediated antigen processing & presentation, organism-specific biosystem; Direct p53 effectors, organism-specific biosystem
• Function: ligase activity; metal ion binding; p53 binding; protein binding; protein homodimerization activity; receptor binding; ubiquitin-protein ligase activity; zinc ion binding; zinc ion binding

Reviews

11/25/2019

Experiments using RCHY1 were very reproducible and allowed me to evaluate the results more accurately.

07/18/2019

Due to stability of RCHY1 was still very good under different experimental conditions, indicating that it has a wide range of applications and adaptability.

04/10/2019

The band definition of RCHY1 in Western blot was very high, which improved the confidence of the experiment.

Q&As

Why RCHY1 attempts to provide supportive information as a marker in early node-negative oral squamous cell carcinoma?

RCHY1 acts as an independent target in early-stage node-negative oral squamous cell carcinoma and may provide patients with more accurate diagnostic and prognostic information.

What is the association between RCHY1 and ovarian, breast cancer, etc.?

The association between RCHY1 and ovarian and breast cancer is mainly manifested in its regulation of hormone receptor expression, migration and invasion.

Is RCHY1 an important driver?

RCHY1, as a Ubiquitin ligase, has been found as a driving factor in a variety of cancers such as liver, prostate, and kidney cancer.

How about the relationship between the expression of RCHY1 and prognosis?

RCHY1 is expressed in different types of cancer, and its high expression is associated with poor prognosis and high risk of metastasis.

Does the polymorphism of RCHY1 predict tumor recurrence?

For breast and ovarian cancer patients, the polymorphisms of RCHY1 are associated with the risk of tumor recurrence and can be used as a biomarker to predict recurrence.

What is the role of RCHY1 in apoptosis?

RCHY1 is involved in regulating apoptosis signaling pathways by mediating the single ubiquitination pathway and promoting apoptosis of tumor cells.